Head-To-Head Contrast: Myovant Sciences (MYOV) vs. Syros Pharmaceuticals (SYRS)

Myovant Sciences (NYSE: MYOV) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Insider & Institutional Ownership

81.1% of Myovant Sciences shares are owned by institutional investors. Comparatively, 48.8% of Syros Pharmaceuticals shares are owned by institutional investors. 3.0% of Myovant Sciences shares are owned by insiders. Comparatively, 33.6% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Myovant Sciences and Syros Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myovant Sciences N/A N/A -$83.44 million ($1.96) -7.55
Syros Pharmaceuticals $320,000.00 1,024.04 -$47.74 million ($2.01) -5.06

Syros Pharmaceuticals has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Myovant Sciences has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of -2.36, meaning that its share price is 336% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Myovant Sciences and Syros Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myovant Sciences 0 0 4 0 3.00
Syros Pharmaceuticals 0 2 6 0 2.75

Myovant Sciences currently has a consensus price target of $22.50, suggesting a potential upside of 52.03%. Syros Pharmaceuticals has a consensus price target of $23.83, suggesting a potential upside of 134.13%. Given Syros Pharmaceuticals’ higher possible upside, analysts clearly believe Syros Pharmaceuticals is more favorable than Myovant Sciences.

Profitability

This table compares Myovant Sciences and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myovant Sciences N/A -90.86% -74.94%
Syros Pharmaceuticals N/A -62.01% -55.65%

Summary

Syros Pharmaceuticals beats Myovant Sciences on 8 of the 12 factors compared between the two stocks.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply